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PLATE-BREAKING CLINICAL TRIALS
Does Addition of Estradiol Improve
the Efficacy of a Rapamycin-Eluting Stent?
Results of the ISAR-PEACE Randomized Trial
Tom Adriaenssens, MD, Julinda Mehilli, MD, Rainer Wessely, MD, Gjin Ndrepepa, MD,
Melchior Seyfarth, MD, Anna Wieczorek, Birgit Blaich, PHD, Raisuke Iijima, MD, Jürgen Pache, MD,
Adnan Kastrati, MD, Albert Schömig, MD
Munich, Germany
Objectives This study aimed to assess the efficacy of a rapamycin plus 17--estradiol–eluting stent versus a rapamycin-
eluting stent in patients with coronary artery disease.
Background Estradiol promotes rapid re-endothelialization of coronary stents in animal models, but it is not known whether
combining this drug with rapamycin represents an improved drug-eluting stent technology in terms of reduced
lumen renarrowing.
Methods In this randomized study, we enrolled 502 patients with de novo lesions in native coronary arteries who were
randomly assigned to receive either a polymer-free, estradiol plus rapamycin-eluting stent (ERES) (n  252) or a
polymer-free, rapamycin-eluting stent (RES) (n  250). The primary end point was in-stent late lumen loss in the
follow-up angiography. Secondary end points were binary angiographic restenosis, target lesion revasculariza-
tion, combined incidence of death and myocardial infarction, and incidence of stent thrombosis during 1 year
after randomization. The study was designed to test for the superiority of the ERES compared with the RES with
respect to in-stent late lumen loss.
Results Late lumen loss (0.52  0.58 mm vs. 0.51  0.58 mm, p  0.83), the incidence of binary angiographic reste-
nosis (17.6% vs. 16.9%, p  0.85), the incidence of target lesion revascularization (14.3% vs. 13.2%, p  0.72),
the combined incidence of death and myocardial infarction (7.9% vs. 8.0%, p  0.98), and the incidence of
stent thrombosis (0.8% vs. 1.2%, p  0.99) were not significantly different between the ERES group and the RES
group.
Conclusions No apparent beneficial effect is obtained by adding estradiol to a polymer-free rapamycin-eluting stent during
the first year after the procedure. (The ISAR-PEACE trial; http://clinicaltrials.gov/ct/show/NCT00402636?
order1; NCT00402636) (J Am Coll Cardiol 2007;49:1265–71) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.021l
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she use of drug-eluting stents (DES) has reduced the need
or reintervention compared with bare-metal stents (BMS)
1). Despite these results, there is an intense ongoing debate
n an increased risk of late stent thrombosis, particularly
fter discontinuation of thienopyridine therapy, and delayed
nset of restenosis, or catch-up phenomenon, with DES
2–4). Lack of or delayed endothelialization associated with
ES is considered an important factor that may precipitate
rom the Deutsches Herzzentrum, Technische Universtität, Munich, Germany. Dr.
astrati reports receiving lecture fees from Bristol-Myers Squibb, Cordis, Glaxo-
mithKline, Lilly, Medtronic, Novartis, and Sanofi-Aventis. Dr. Schömig reports
eceiving unrestricted grant support for the Department of Cardiology he chairs from
mersham/General Electric, Bayerische Forschungsstiftung, Bristol-Meyers Squibb,p
ordis, Cryocath, Guidant, Medtronic, Nycomed, and Schering.
Manuscript received February 12, 2007; accepted February 16, 2007.ate stent thrombosis (5). There are limited data regarding
he effect of rapamycin on endothelial (re)growth (6).
ecent findings from a human study suggest that endothe-
ial dysfunction is frequently apparent after implantation of
sirolimus-eluting stent (7). In addition, there is strong
vidence that a rapid re-endothelialization attenuates neo-
ntima formation after vascular injury (8,9), and promotion
f endothelial recovery is regarded as the next target for
estenosis (10). Estradiol has been shown to promote rapid
e-endothelialization of the stent and to reduce restenosis
fter percutaneous coronary interventions (PCIs) in animal
odels (11–13). Thus, by promoting re-endothelialization,
stradiol has the potential of favorably affecting the risk of
hrombosis and restenosis after DES implantation. It may
erve as a useful adjunct to rapamycin with established
ronounced antiproliferative effects.
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Rapamycin Plus Estradiol-Eluting Stent March 27, 2007:1265–71We designed a randomized
study to compare the efficacy of
a polymer-free, estradiol plus
rapamycin-eluting stent (ERES)
with that of a polymer-free,
rapamycin-eluting stent (RES)
in patients with coronary artery
disease. The stent platform used
was a microporous stainless steel
stent that allows for a polymer-
free drug coating.
Methods
Study population and protocol.
Patients who were at least 18
ears old, had stable or unstable angina or a positive stress
est, and were to undergo PCIs for de novo lesions in a
ative coronary artery were considered eligible for this
tudy. Pregnant women; patients with an acute ST-segment
levation myocardial infarction; malignancies or other co-
orbid conditions with a life expectancy 12 months;
arget lesion located in the left main trunk; and a contrain-
ication or known allergy to aspirin, heparin, thienopyri-
ines, rapamycin, estradiol, or stainless steel were consid-
red ineligible for the study. The study protocol was
pproved by the local ethics committee. All patients gave
heir written informed consent for participation in this trial.
At least 2 h before undergoing catheterization, patients
eceived a loading dose of 600 mg of clopidogrel. Random-
zation was performed after wiring of the target vessel using
ealed, opaque envelopes containing a computer-generated
andom sequence. No stratification was performed. Patients
ere assigned to receive either ERES or RES. The stent
latform used in this study has been described in detail
reviously (14,15). Both rapamycin and estradiolvalerat
ere in 1% concentrations.
For determination of pharmacologic release kinetics,
RES and RES (n  3 for each group) were deployed ex
ivo and incubated in 1 ml of phosphate-buffered saline at
7°C in screw-cap tubes. Samples harvested at the indicated
ime points were subjected to ultraviolet spectrophotometric
nalysis by using a SAFIRE multiplate reader (Tecan
chweiz Trading AG, Männedorf, Switzerland). A calibra-
ion curve was established by use of the peak absorbance
avelength of 280 nm (A280) for rapamycin in phosphate-
uffered saline and served as a basis for the calculation of
espective concentrations and, hence, of total amounts of
he substance in each sample. Interference of absorption
easurement by estradiolvalerat at 280 nm was ruled out by
omparison of A280 of stock solutions containing either
apamycin alone (1%) or a mixture of rapamycin and
stradiolvalerat (1%/1%) showing virtually the same values
or both samples (data not shown). This is due to a
onsiderably lower absorbance level of estradiolvalerat at
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
ERES  estradiol plus
rapamycin-eluting stent(s)
IVUS  intravascular
ultrasound
PCI  percutaneous
coronary intervention
RES  rapamycin-eluting
stent(s)80 nm compared with rapamycin at the same concentra-ion. Figure 1 shows a marked slower release of rapamycin
rom ERES. At 1 month, total release of rapamycin was
5% from RES and 60% from ERES.
Aspirin and unfractionated heparin were administered per
tandard practice; the use of abciximab (ReoPro, Lilly, Bad
omburg, Germany) was generally restricted to patients with
cute coronary syndromes (positive troponin or ST-segment
epression on surface electrocardiogram). After the procedure,
atients were maintained on aspirin 100 mg twice daily indefi-
itely, and clopidogrel 75 mg twice daily until discharge and 75
g daily for at least 6 months. Other medicaments such as
eta-blockers, statins, and angiotensin-converting enzyme inhib-
tors were given as indicated. After enrollment, patients remained
n hospital for at least 48 h. Electrocardiograms were recorded,
nd blood was collected for determination of creatine kinase and
ts MB isoenzyme before randomization, and every 8 h for the first
4 h after randomization and daily until hospital discharge.
linical follow-up by phone contact was scheduled at 1 and 12
onths. All patients were asked to return for repeat coronary
ngiography between 6 and 8 months after randomization or
arlier, if anginal symptoms had developed.
ata management, end points, and definitions. Relevant
ata were collected and entered into a computer database by
pecialized personnel of the ISAR (Intracoronary Stenting
nd Angiographic Restenosis) Center. All data were verified
gainst source documentation, and all adverse events were
djudicated by an event committee blinded to treatment
llocation. Baseline, postprocedural, and follow-up cinean-
iograms were forwarded to the Quantitative Angiographic
ore Laboratory (ISAR Center, Munich, Germany) for
ssessment by experienced technicians unaware of the treat-
ent allocation. Angiographic image acquisition of the
arget lesion was done after intracoronary administration of
Figure 1 Release Kinetics of Rapamycin
From the ERES and RES
Kinetics are displayed as cumulative release of rapamycin over time in percent
of total rapamycin on the stents ( SD). ERES  estradiol plus rapamycin-
eluting stent; RES  rapamycin-eluting stent.
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March 27, 2007:1265–71 Rapamycin Plus Estradiol-Eluting Stentitroglycerin, and the same single worst view projection was
easured at all time points. Qualitative morphologic lesion
haracteristics were characterized using standard criteria
16). Off-line quantitative coronary angiographic analysis
as performed using the automated edge detection system
QCA-CMS version 6.0, Medis, Medical Imaging Systems,
eiden, the Netherlands). The contrast-filled non-tapered
atheter tip was used for calibration. The reference diameter
as measured by interpolation. Minimal lumen diameter
as measured within the stent and within the 5-mm
roximal and distal edges of the stent. Quantitative analysis
as performed in the in-stent area (in-stent analysis) and in
he in-segment area including the stented segment as well as
oth 5-mm margins proximal and distal to the stent
in-segment analysis).
The primary end point of the study was in-stent late
umen loss. Secondary end points were the binary angio-
raphic restenosis (diameter stenosis of at least 50% based
n in-segment analysis) at follow-up angiography, the need
or target lesion revascularization due to restenosis in the
resence of symptoms or signs of ischemia, the combined
ncidence of death and myocardial infarction, and the
ncidence of stent thrombosis during the 12-month follow-
p. The diagnosis of myocardial infarction required the
resence of new Q waves in the electrocardiogram and/or
levation of creatine kinase or its MB isoenzyme at least 3
imes the upper limit of normal in 2 blood samples. Stent
hrombosis was defined as a target lesion occlusion with
hrombolysis In Myocardial Infarction flow grade 0 or 1
ccompanied by angiographically visible thrombus and/or
cute coronary syndrome. Retrospectively, stent thrombosis
as also assessed based on the definitions of the Academic
esearch Consortium (ARC) (17).
tatistical methods. The study hypothesis was that ERES
as superior to RES in terms of decreased late lumen loss.Figure 2 Flow Chart of Study Participantsssuming a late lumen loss of 0.48 mm with the RES and
hoosing a power of 80%, 190 patients were required in each
roup to demonstrate a significant difference of 0.16 mm in
avor of ERES at a 2-sided alpha level of 0.05. We enrolled
total of 502 patients to accommodate for possible missing
ollow-up angiograms.
The analyses were performed on an intention-to-treat
asis. In patients with multilesion interventions, only the
rst treated lesion that served for randomization was in-
luded in the analysis. Categoric variables are summarized
s counts or percentages and compared using chi-square or
isher exact test (when expected cell values were 5).
ontinuous variables are expressed as mean  SD and
ompared with the Student t test. Survival analysis was
erformed by applying the Kaplan-Meier method; differ-
nces in survival parameters were checked for significance by
he log-rank test. All analyses were performed using S-Plus
.5 statistical package (Insightful Corp., Seattle, Washing-
on). A 2-sided p value 0.05 was considered to indicate
tatistical significance.
esults
aseline characteristics and procedural results. A total of
02 patients were enrolled in this study; 252 patients were
ssigned to the ERES group and 250 to the RES group.
igure 2 shows the flow chart of study participants. Baseline
emographic and clinical data are shown in Table 1.
ngiographic and procedural characteristics are shown in
able 2. Data were well matched between the 2 groups.
mplantation of the assigned stent was successful in all but
(99.6%) patient in the ERES group and in all patients in
he RES group. Only a small proportion of patients received
bciximab periprocedurally (Table 2).
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Rapamycin Plus Estradiol-Eluting Stent March 27, 2007:1265–71At discharge, beta-blockers (97.2% vs. 97.6%, p  0.80),
ngiotensin-converting enzyme inhibitors (82.9% vs. 84.0%,
 0.75), and statins (91.7% vs. 92.4%, p  0.76) were
rescribed in similar proportions of patients in the ERES
nd RES groups. There were also no significant differences
etween the 2 groups regarding the actual duration of
lopidogrel therapy: 4 weeks in 0.4% and 1.2%, 6 months in
9.4% and 17.2%, and 1 year in 80.2% and 81.6% in the
RES and RES groups, respectively (p  0.50).
ngiographic restenosis. Follow-up angiography was per-
ormed in 204 patients (81.0%) in the ERES group and in 201
atients (80.4%) in the RES group (p 0.97). Reasons for failure
o perform follow-up angiography are shown in Figure 2.
In-stent late lumen loss was 0.52  0.58 mm among
atients in the ERES group and 0.51  0.58 mm among
atients in the RES group (p  0.83). Figure 3 shows the
verlapping cumulative distribution curves of late lumen loss
Baseline Demographic and Clinical Characterist
Table 1 Baseline Demographic and Clinical
Characteristic
R
Age (yrs)
Women
Diabetes mellitus
Current smoker
Arterial hypertension
Hypercholesterolemia
Unstable angina
Non–ST-segment elevation myocardial infarction
Prior myocardial infarction
Prior aortocoronary bypass surgery
Left ventricular ejection fraction (%)
Serum creatinine (mg/dl)
Data are mean  SD or number of patients (%).
Angiographic and Procedural Data
Table 2 Angiographic and Procedural Data
Characteristic
E
Ra
Target vessel
Left anterior descending coronary artery
Left circumflex coronary artery
Right coronary artery
Complex (type B2/C) lesions
Chronic total occlusions
Vessel size (mm)
Lesion length (mm)
Initial minimal lumen diameter (mm)
Initial diameter stenosis (%)
Maximal balloon pressure (atm)
Maximal balloon diameter (mm)
Length of stented segment (mm)
Final minimal lumen diameter (mm)
Final diameter stenosis (mm)
Periprocedural abciximab therapyData are mean  SD or number of patients (%).n the 2 study groups. The other quantitative parameters of
estenosis were also comparable between the 2 groups
Table 3). The incidence of binary angiographic restenosis
as 17.6% in the ERES group and 16.9% in the RES group
p  0.85) (Fig. 4).
tent thrombosis. According to the protocol-based defini-
ion, 2 patients (0.8%) in the ERES group (22 and 249 day
fter DES implantation, respectively) and 3 patients (1.2%) in
he RES group (1, 11, and 13 days after DES implantation,
espectively) incurred stent thrombosis (p  0.99) within 1
ear after randomization; all of these patients were on clopi-
ogrel treatment as they incurred this complication.
Using the ARC criteria, definite stent thrombosis was
bserved in 2 patients (0.8%) in the ERES group and 3
atients (1.2%) in the RES group (p  0.99). In addition,
here were 6 cases of possible stent thrombosis (3 in each
roup) and no cases of probable stent thrombosis.
acteristics
diol Plus
ycin Group
 252)
Rapamycin
Group
(n  250) p Value
 10.3 67.4 10.5 0.24
6 (22) 64 (26) 0.37
6 (30) 72 (29) 0.74
8 (19) 45 (18) 0.76
6 (62) 166 (66) 0.29
4 (61) 172 (69) 0.07
9 (31) 73 (29) 0.60
9 (23) 50 (20) 0.35
0 (32) 84 (34) 0.66
3 (9) 18 (7) 0.43
 10.9 53.5 13.0 0.06
 0.55 1.08 0.56 0.20
ol Plus
in Group
252)
Rapamycin
Group
(n  250) p Value
0.30
38) 107 (43)
30) 60 (24)
33) 83 (33)
69) 192 (77) 0.06
2) 6 (2) 0.99
0.5 2.78 0.50 0.90
7.2 12.6 6.2 0.17
0.46 1.10 0.50 0.63
14.9 60.3 16.1 0.59
2.9 14.3 2.8 0.89
0.51 2.90 0.48 0.25
7.9 21.3 8.6 0.69
0.44 2.59 0.43 0.12
5.9 9.9 6.1 0.11
8.7) 21 (8.4) 0.89ics
Char
Estra
apam
(n
66.3
5
7
4
15
15
7
5
8
2
55.6
1.02stradi
pamyc
(n 
95 (
75 (
82 (
175 (
6 (
2.77
13.5
1.08
61.0
14.3
2.85
21.6
2.53
10.8
22 (
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March 27, 2007:1265–71 Rapamycin Plus Estradiol-Eluting Stentlinical outcomes. Five patients (2.0%) in the ERES group
nd 6 patients (2.4%) in the RES group died at 1 year (p 
.75); all of them were on clopidogrel treatment when they
ied. The combined 12-month incidence of death and myo-
ardial infarction was comparable between the 2 groups (7.9%
n the ERES group versus 8.0% in the RES group, p  0.98)
Fig. 5). Target lesion revascularization rate was 14.3% in the
RES group and 13.2% in the RES group (p 0.72) (Fig. 4).
iscussion
n this randomized study, we compared the efficacy of 2
ypes of polymer-free DES. Using an identical stent plat-
orm, the first stent was coated with a combination of 2
rugs, estradiol and rapamycin, and the second stent was
oated with rapamycin alone. We could not see any differ-
nces in terms of restenosis and clinical outcomes between
hese 2 DES. Before commenting on these results, we
hould acknowledge some limitations of the present study.
he experimentally shown promotion of endothelialization
y estradiol has the potential of reducing the risk of both
eointima formation and stent thrombosis. The present
Figure 3 Cumulative Frequency Curves of In-Stent Late Lumen
Loss at Follow-Up Angiography for the 2 DES Groups
DES  drug-eluting stent; other abbreviations as in Figure 1.
Quantitative Findings at Follow-Up Angiography
Table 3 Quantitative Findings at Follow-Up A
Characteristic
Estradiol Plus
Rapamycin Group
(n  204)
Late lumen loss (mm)
In-stent 0.52 0.58
In-segment 0.38 0.55
Minimal lumen diameter (mm)
In-stent 2.01 0.71
In-segment 1.82 0.63
Diameter stenosis (%)
In-stent 28.18 21.20
In-segment 34.97 18.76Data are mean  SD or number of patients (%).tudy was only powered to assess the additive effects of
stradiol on late lumen loss due to neointima formation.
oth the relatively limited number of patients and duration
f follow-up do not enable any conclusions relative to the
ossible influence of estradiol in the risk of stent thrombosis
n clinical settings. However, we have also to recognize
hat none of the previous randomized trials on the value
f new DES devices has been sufficiently powered to
ssess the issue of stent thrombosis. Another limitation is
lso that the present study lacks intravascular imaging
odalities such as intravascular ultrasound (IVUS), an-
ioscopy, and optical coherence tomography that would
ave allowed evaluation of stent strut coverage in the 2 study
roups.
Endothelium, with its inhibitory effects on platelet ag-
regation, monocyte adhesion, and smooth muscle cell
roliferation, has been well recognized for its role in vascular
ealing after vascular trauma induced by balloon angioplasty
r stenting. Pathological studies have shown delayed endo-
helialization after DES implantation (5). Therefore, strat-
Figure 4 Incidences of Angiographic and Clinical
Restenosis for the ERES and RES Groups
TLR  target lesion revascularization; other abbreviations as in Figure 1.
graphy
Rapamycin
Group
(n  201) p Value
0.51 0.58 0.83
0.38 0.53 0.87
2.10 0.74 0.22
1.92 0.68 0.15
27.05 21.07 0.59
33.50 19.06 0.43ngio
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Rapamycin Plus Estradiol-Eluting Stent March 27, 2007:1265–71gies to improve vascular healing after intervention-induced
njury may prevent thrombosis and restenosis and improve
linical outcomes (18,19).
During the last decade, many experimental studies
ave highlighted the potential vasculoprotective effects of
stradiol, via a number of molecular and cellular mecha-
isms, indicating that estradiol can inhibit smooth mus-
le cell proliferation and migration and accelerate re-
ndothelialization (20–22). There are also data from several
maller retrospective analyses suggesting beneficial effects of
strogen replacement therapy after PCI in postmenopausal
omen (23,24). Considering, however, the increased risk of
reast and ovarian cancer with estradiol therapy in women
nd its feminizing effects in men, research efforts have
oncentrated on the prevention of restenosis by local deliv-
ry of the compound with the advantage of using the
mallest effective dose required to achieve a sufficient drug
oncentration at the vessel wall to prevent neointima for-
ation (25). Results from recent animal studies show that
ocal delivery of estradiol, either via an infusion catheter or
mpregnated on a stent, inhibits neointimal proliferation
nd may improve endothelial repair and recovery (11–
3,26). These promising results formed the basis of applying
his technology in humans. The EASTER (Estrogen And
tents To Eliminate Restenosis) trial represented the first
uman experience with 17--estradiol–eluting stents (27).
he trial included 30 consecutive patients who underwent
7--estradiol BiodivYsio (Biocompatibles Ltd., London,
nited Kingdom) stent implantation for the treatment of de
ovo coronary lesions. Control angiography at 6 months
howed that only 2 patients exceeded the 50% intra-stent
arrowing, and no edge restenosis was observed; IVUS
xamination at 6 months demonstrated a low amount of
ntimal hyperplasia and late lumen loss (27). Encouraged by
hese initial positive results, the same group of investigators
erformed a new randomized trial by assigning 95 patients
Figure 5 Probability of Survival Free of MI
for the ERES Group and for the RES Group
MI  myocardial infarction; other abbreviations as in Figure 1.ith de novo coronary lesions to a BMS, a fast-release mstradiol-eluting stent, or a moderate-release estradiol-
luting stent (28). The trial demonstrated no benefit among
atients treated with estradiol-eluting stents compared with
atients treated with a BMS at 6 months. Intravascular
ltrasound IVUS measurements performed at 6 months of
ollow-up did not indicate any statistically significant dif-
erences among the 3 arms with respect to neointimal
yperplasia volume, volumetric plaque burden, and in-stent
olume obstruction (28). A recent randomized trial of 108
atients with de novo lesions in native coronary arteries did
ot indicate any superiority of 17--estradiol–coated stent
ver control phosphorylcholine-coated stent regarding an-
iographic and clinical outcomes (29). In another recent
andomized placebo-controlled trial, 299 patients were as-
igned to either local delivery of estradiol or placebo (infused
n the coronary artery) at the time of stenting (30). The
tudy showed that the procedure was safe and that the
nfusion of estradiol led to a reduction in the need for urgent
CI at 6 months, but it did not significantly reduce
ngiographic late loss at 6 months (30).
The present study represents the largest clinical experi-
nce with 17--estradiol–eluting stents for the prevention
f restenosis and the first clinical trial to assess a combina-
ion of drugs such as estradiol and rapamycin in the settings
f DES technology. The clinical outcomes at 1 year confirm
ur earlier reports regarding the safety and efficacy of the
olymer-free, RES platform (15,31,32); however, the
resent study failed to provide evidence in favor of an
dditional effect of estradiol coating on top of that of
apamycin regarding inhibition of neointimal proliferation.
t is highly improbable that the lack of additional positive
ffects by adding estradiol to rapamycin is related to the
lowing down of the release kinetics of rapamycin by
stradiol. A slower release of rapamycin is expected to
otentiate its inhibitory effect on neointima formation. This
s suggested by both direct (33) and indirect (31,34) com-
arisons of neointima measures between slow- and fast-
elease RES. In fact, both groups in the present study
howed late lumen loss measures greater than those ob-
erved for polymer-based sirolimus-eluting stents (34) but
ower than the in-stent late lumen loss of 0.61 mm observed
or phosphorylcholine polymer-based zotarolimus-eluting
tents (35). On the other hand, the in-stent late lumen loss
f 0.52 mm in the ERES group of our study is similar to the
.54 mm value of this index in the estradiol group of the
ASTER trial (27) and much lower than the 0.82 and
.86 mm values reported recently for moderate- and fast-
elease estradiol-eluting stents (28).
The disparate results between the animal models and
ecent clinical studies regarding the efficacy of estrogen-
oating stents remain hard to explain. However, several
xplanations may be offered for the failure of estrogen-
oating to improve angiographic and clinical outcomes in
ur study. First, in the presence of powerful inhibitory
ctions of rapamycin on vascular smooth muscle cells, there
ay be no further inhibition of smooth muscle cell prolif-
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March 27, 2007:1265–71 Rapamycin Plus Estradiol-Eluting Stentration by locally delivered estrogen. Although the re-
ndothelialization-promoting properties of estrogen have
een demonstrated (11–13), they may not be sufficient to
ounteract the inhibitory effects of rapamycin on the re-
ndothelialization process. Second, estrogen promotion of
he re-endothelialization process may depend on its con-
entration at the site of vascular injury, but the optimal local
ose in humans is still not known (12). Finally, we cannot
xclude that a follow-up longer than 1 year might be
equired to detect the advantages provided by estradiol
egarding prevention of late stent thrombosis after cessation
f thienopyridine therapy.
In conclusion, no apparent beneficial effect is obtained by
dding estradiol to a polymer-free RES during the first year
fter the procedure.
eprint requests and correspondence: Dr. Julinda Mehilli,
eutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Ger-
any. E-mail: mehilli@dhm.mhn.de.
EFERENCES
1. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing
sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;
356:1030–9.
2. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in
drug-eluting coronary stents after discontinuation of antiplatelet ther-
apy. Lancet 2004;364:1519–21.
3. Park DW, Hong MK, Mintz GS, et al. Two-year follow-up of the
quantitative angiographic and volumetric intravascular ultrasound
analysis after nonpolymeric paclitaxel-eluting stent implantation: late
“catch-up” phenomenon from ASPECT study. J Am Coll Cardiol
2006;48:2432–9.
4. Wessely R, Kastrati A, Schömig A. Late restenosis in patients
receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med
2005;143:392–4.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in
humans: delayed healing and late thrombotic risk. J Am Coll Cardiol
2006;48:193–202.
6. Wessely R, Schömig A, Kastrati A. Sirolimus and paclitaxel on
polymer-based drug-eluting stents: similar but different. J Am Coll
Cardiol 2006;47:708–14.
7. Serry R, Penny WF. Endothelial dysfunction after sirolimus-eluting
stent placement. J Am Coll Cardiol 2005;46:237–8.
8. Kipshidze N, Dangas G, Tsapenko M, et al. Role of the endothelium
in modulating neointimal formation: vasculoprotective approaches to
attenuate restenosis after percutaneous coronary interventions. J Am
Coll Cardiol 2004;44:733–9.
9. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of
endothelial progenitor cells reduces neointima formation after vascular
injury. Circ Res 2003;93:e17–24.
0. Losordo DW, Isner JM, Diaz-Sandoval LJ. Endothelial recovery: the
next target in restenosis prevention. Circulation 2003;107:2635–7.
1. Chandrasekar B, Nattel S, Tanguay JF. Coronary artery endothelial
protection after local delivery of 17beta-estradiol during balloon
angioplasty in a porcine model: a potential new pharmacologic
approach to improve endothelial function. J Am Coll Cardiol 2001;
38:1570–6.
2. Chandrasekar B, Sirois MG, Geoffroy P, Lauzier D, Nattel S,
Tanguay JF. Local delivery of 17beta-estradiol improves reendotheli-
alization and decreases inflammation after coronary stenting in a
porcine model. Thromb Haemost 2005;94:1042–7.
3. Chandrasekar B, Tanguay JF. Local delivery of 17-beta-estradiol
decreases neointimal hyperplasia after coronary angioplasty in a por-
cine model. J Am Coll Cardiol 2000;36:1972–8.
4. Dibra A, Kastrati A, Mehilli J, et al. Influence of stent surface
topography on the outcomes of patients undergoing coronary stenting:a randomized double-blind controlled trial. Catheter Cardiovasc Interv
2005;65:374–80.
5. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima
formation by a novel drug-eluting stent system that allows for
dose-adjustable, multiple, and on-site stent coating. Arterioscler
Thromb Vasc Biol 2005;25:748–53.
6. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic
and clinical determinants of procedural outcome with angioplasty for
multivessel coronary disease. Implications for patient selection. Mul-
tivessel Angioplasty Prognosis Study Group. Circulation 1990;82:
1193–202.
7. Mauri L, Hsieh W, Massaro JM, Ho KKL, D’Agostino R, Cutlip
DE. Stent thrombosis in randomized clinical trials of drug-eluting
stents. N Engl J Med 2007;356:1020–9.
8. Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis.
Prog Cardiovasc Dis 1997;39:343–50.
9. Vanhoutte PM, Mombouli JV. Vascular endothelium: vasoactive
mediators. Prog Cardiovasc Dis 1996;39:229–38.
0. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF.
Estradiol accelerates reendothelialization in mouse carotid artery
through estrogen receptor-alpha but not estrogen receptor-beta. Cir-
culation 2001;103:423–8.
1. Dai-Do D, Espinosa E, Liu G, et al. 17 beta-estradiol inhibits
proliferation and migration of human vascular smooth muscle cells:
similar effects in cells from postmenopausal females and in males.
Cardiovasc Res 1996;32:980–5.
2. White MM, Zamudio S, Stevens T, et al. Estrogen, progesterone, and
vascular reactivity: potential cellular mechanisms. Endocr Rev 1995;
16:739–51.
3. Khan MA, Liu MW, Singh D, et al. Long-term (three years) effect of
estrogen replacement therapy on major adverse cardiac events in
postmenopausal women after intracoronary stenting. Am J Cardiol
2000;86:330–3.
4. O’Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen
replacement therapy and restenosis after percutaneous coronary inter-
ventions. J Am Coll Cardiol 1996;28:1111–8.
5. Schömig A, Kastrati A, Wessely R. Prevention of restenosis by systemic
drug therapy: back to the future? Circulation 2005;112:2759–61.
6. New G, Moses JW, Roubin GS, et al. Estrogen-eluting,
phosphorylcholine-coated stent implantation is associated with re-
duced neointimal formation but no delay in vascular repair in a porcine
coronary model. Catheter Cardiovasc Interv 2002;57:266–71.
7. Abizaid A, Albertal M, Costa MA, et al. First human experience with
the 17-beta-estradiol-eluting stent: the Estrogen And Stents To
Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 2004;43:
1118–21.
8. Abizaid A. ETHOS I: no incremental benefit with estradiol eluting
stents. Paper presented at: Transcatheter Cardiovascular Therapeutics;
October 24, 2006; Washington, DC.
9. Airoldi F, Di Mario C, Ribichini F, et al. 17-beta-estradiol eluting
stent versus phosphorylcholine-coated stent for the treatment of native
coronary artery disease. Am J Cardiol 2005;96:664–7.
0. Tanguay JF, Labinaz M, Dzavik V, Colizza F. Local delivery of
17-beta-estradiol: 6-month results of the ESTRACURE trial. Paper
presented at: World Congress of Cardiology; September 5, 2006;
Barcelona, Spain.
1. Hausleiter J, Kastrati A, Wessely R, et al. Prevention of restenosis by
a novel drug-eluting stent system with a dose-adjustable, polymer-free,
on-site stent coating. Eur Heart J 2005;26:1475–81.
2. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a
nonpolymer-based rapamycin-eluting stent versus a polymer-based
paclitaxel-eluting stent for the reduction of late lumen loss. Circulation
2006;113:273–9.
3. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and
intravascular ultrasound follow-up after implantation of sirolimus-
eluting stents in human coronary arteries. Circulation 2003;107:381–3.
4. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus
standard stents in patients with stenosis in a native coronary artery.
N Engl J Med 2003;349:1315–23.
5. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind,
multicenter study of the Endeavor zotarolimus-eluting phosphoryl-
choline-encapsulated stent for treatment of native coronary artery
lesions: clinical and angiographic results of the ENDEAVOR II trial.
Circulation 2006;114:798–806.
